THOMAS MANGIACAPRE: Open Payments
NPI 1366986374 · WINSTON SALEM, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$645 in 31 payments from 9 companies in 2025. Trend: 2023 $790 · 2024 $743 · 2025 $645
Food & beverage: $645
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 9 | $182 |
| ABBVIE INC. | 6 | $106 |
| SK Life Science, Inc. | 3 | $93 |
| Merck Sharp & Dohme LLC | 5 | $91 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $68 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $45 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 1 | $24 |
| Alexion Pharmaceuticals, Inc. | 1 | $19 |
| Novartis Pharmaceuticals Corporation | 1 | $17 |
Products named: ELIQUIS, ZERBAXA, DALVANCE, XIFAXAN, JARDIANCE, LifeVest, EMBLAVEO, ULTOMIRIS.
Industry payments across NC — which companies pay providers there.
